ReviewNature reviews. Gastroenterology & hepatology2025
Public health policies to prevent alcohol-related liver disease.
Review in Nature reviews. Gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Changing epidemiology and etiology of hepatocellular carcinoma in Europe: implications for clinical practice and health policy.The Lancet regional health. Europe · 2026Review
- Ethanol-Tolerant Lactobacillus rhamnosus L7 Ameliorates Alcohol-Induced Liver Injury in Mice by Inhibiting the TLR4/MyD88/NF-κB Inflammatory Signaling Pathway and Restoring Gut Microbiota Homeostasis.Probiotics and antimicrobial proteins · 2026Article
- Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe.The Lancet regional health. Europe · 2026Review
- The global epidemiology of alcohol-associated liver disease.Hepatology communications · 2026Review
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026Review
- Article
- Review
- Epidemiological trends in alcoholic cardiomyopathy burden: A 32-year global and Chinese analysis (1990-2021) with projections to 2036.PloS one · 2025Article
- The C-reactive Protein-Triglyceride-Glucose Index in Relation to Liver Disease.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol-related liver disease (ALD) is a major cause of morbidity and premature mortality around the world, with a substantial cost to individuals and to health-care systems. The incidence of ALD is closely associated with alcohol intake, and it is a preventable disease. There is clear evidence that public health measures to reduce alcohol consumption are effective, which in turn can have a positive effect on ALD. Effective policy includes controlling the price of alcohol, limiting or banning alcohol advertising and restricting the availability of alcohol. The strength of public health policy depends on the political willingness to develop robust strategies. However, effective lobbying of policy-makers by the alcohol industry and lack of political will are barriers to the implementation of these measures, resulting in suboptimal national alcohol control policies. Clinicians are well-placed to campaign for effective public health policy regarding alcohol to reduce the prevalence of ALD for the benefit of patients, their families and wider society. In this Perspective, we summarize the evidence for public health policies that affect alcohol consumption and the prevalence of ALD.
Indexed as
Identifiers
40461606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.